Aldosterone in Diabetic Nephropathy

Universidad de los Andes, Chile160 enrolled

Overview

The purpose of this study is to determine whether spironolactone are effective in the reduction of albuminuria and diastolic disfunction of subjects with diabetic nephropathy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

160

Conditions

Diabetic Nephropathy

Interventions

SpironolactoneDRUG

25 mg per day for 9 months

PlaceboDRUG

Placebo 1 tablet per day for nine months

Eligibility

Sex: ALLMin age: 30 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diabetic subjects with maximum ten years after diagnostic * Diabetic nephropathy with albuminuria * Normal renal function * Diastolic disfunction * Taking a IECA or ARA drug family previously Exclusion Criteria: * Diabetics subjects with macroangiopathy * Acute coronary syndrome in the three months before * Hyperkalemia \> 5.5 mEq/L * Pregnancy

Locations (1)

University of Los Andes

Santiago, Santiago Metropolitan, Chile

RECRUITING

Outcomes

Primary Outcomes

Reduction of albuminuria

Time frame: 9 months

Secondary Outcomes

Reduction of diastolic disfunction

Time frame: 9 months

Central Contacts

Francisco G Espinoza, MD

CONTACT

56 - 2 -91380529 fespinoz@mi.cl

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.